Streptococcus Salivarius BLIS K12
Also known as: Streptococcus salivarius K12, BLIS K12, Streptococcus salivarius BLIS K12
Overview
*Streptococcus salivarius* BLIS K12 is a probiotic strain derived from the human oral cavity, distinguished by its production of bacteriocins, notably salivaricin A2 and B. These bacteriocins inhibit the growth of pathogenic bacteria, making BLIS K12 valuable for promoting oral health and preventing infections. It is available in various forms, including lozenges and tablets, designed for oral administration. Research suggests its efficacy in reducing oral mucositis in cancer patients undergoing radiotherapy and in preventing common infections like pharyngitis and acute otitis media, particularly in children. While research is ongoing, current evidence supports its role as a preventative measure against specific oral and throat infections. The strain's localized action in the oral cavity minimizes systemic effects, contributing to its safety profile.
Benefits
*Streptococcus salivarius* BLIS K12 demonstrates several evidence-based benefits, primarily in oral and upper respiratory health. It significantly reduces the incidence and severity of oral mucositis in patients undergoing radiotherapy for head and neck cancers, as shown in a randomized, double-blind, placebo-controlled trial [1]. BLIS K12 is also effective in preventing pharyngitis and acute otitis media, particularly in children, by inhibiting pathogens such as *Streptococcus pyogenes* and *Haemophilus influenzae* [3][4][5]. Some studies suggest it may reduce halitosis by inhibiting bacteria that produce volatile sulfur compounds [3]. These benefits are most pronounced in individuals prone to recurrent oral or upper respiratory infections or those undergoing cancer treatment affecting the oral cavity. Further research is needed to fully quantify the effect sizes and long-term benefits.
How it works
*Streptococcus salivarius* BLIS K12 exerts its beneficial effects through the production of lantibiotics, specifically salivaricin A2 and B. These bacteriocins inhibit the growth of pathogenic bacteria by disrupting their cell membranes and interfering with essential cellular processes. BLIS K12 acts locally within the oral cavity, colonizing the oral mucosa and creating a protective barrier against invading pathogens. This localized action prevents systemic absorption and reduces the risk of systemic side effects. The strain's presence in the oral cavity helps to maintain a balanced microbial environment, preventing the overgrowth of harmful bacteria and promoting overall oral health.
Side effects
*Streptococcus salivarius* BLIS K12 is generally considered safe for consumption, with a low risk of adverse effects. Clinical trials have not reported any significant side effects associated with its use [1][3]. Due to its localized action in the oral cavity, systemic side effects are unlikely. There are no known drug interactions or contraindications associated with BLIS K12. It is considered safe for use in both children and adults. However, as with any supplement, individuals with compromised immune systems or underlying health conditions should consult with a healthcare professional before use. While rare, some individuals may experience mild gastrointestinal discomfort. No severe adverse events have been documented in the available literature.
Dosage
The recommended dosage of *Streptococcus salivarius* BLIS K12 typically ranges from 1 to 5 billion CFU (colony-forming units) per day. A minimum effective dose is generally considered to be 1 billion CFU [3][5]. It is often administered in lozenge or tablet form to allow for direct contact with the oral mucosa. The optimal timing for administration is once daily, preferably after meals. While a maximum safe dose has not been definitively established, exceeding the recommended dosage is unlikely to provide additional benefits. Due to its localized action, absorption factors and required cofactors are not significant considerations. Proper storage is essential to maintain the viability of the probiotic.
FAQs
How should I store BLIS K12?
Store in a cool, dry place, away from direct sunlight and heat, to maintain the viability of the probiotic bacteria. Check the product label for specific storage instructions.
Is BLIS K12 safe for children?
Yes, BLIS K12 is generally considered safe for children and has been used in studies involving children with recurrent infections [5]. Consult a pediatrician for specific dosage recommendations.
When is the best time to take BLIS K12?
It is best taken once daily, preferably after meals, to allow for optimal colonization of the oral cavity. Consistency is key for achieving the desired benefits.
How long does it take to see results?
It may take several weeks of consistent use to notice the full benefits of BLIS K12. Individual results may vary depending on the specific condition being addressed.
Is BLIS K12 a substitute for antibiotics?
No, BLIS K12 is not a substitute for antibiotics. It is used for prevention and maintenance of oral health, not for treating acute bacterial infections. Consult a doctor for infections.
Research Sources
- https://ascopubs.org/doi/10.1200/JCO.23.00837 – This prospective, randomized, double-blind, placebo-controlled trial involving 160 patients with head and neck cancers undergoing radiotherapy found that *Streptococcus salivarius* BLIS K12 significantly reduced the incidence and duration of severe oral mucositis. The study highlights the potential of BLIS K12 as a preventative measure for oral mucositis in cancer patients.
- https://www.mdpi.com/2673-8007/4/3/91 – This in vitro study investigated the impact of synbiotic sugars on lantibiotic production by BLIS K12. The findings suggest that raffinose and galactose enhance the production of salivaricin A2 and B, potentially increasing the efficacy of BLIS K12 as a probiotic. However, the results need to be confirmed in human studies.
- https://www.nutrafoods.eu/index.php/nutra/article/download/30/25 – This resource discusses the effectiveness of *Streptococcus salivarius* K12 for the treatment and/or prevention of sore throat. It provides insights into the potential benefits of this probiotic strain in managing upper respiratory tract infections, although the specific study design and results require further examination within the linked document.
- https://www.researchgate.net/publication/330135235_Effectiveness_of_the_probiotic_Streptococcus_salivarius_K12_for_the_treatment_andor_prevention_of_sore_throat_a_systematic_review – This systematic review examines the effectiveness of *Streptococcus salivarius* K12 in treating and preventing sore throat. It synthesizes findings from multiple studies to assess the overall evidence supporting the use of this probiotic for upper respiratory tract infections, providing a comprehensive overview of its potential benefits and limitations.
- https://www.mdpi.com/2075-1729/14/12/1613 – This multicenter, open, non-randomized, controlled clinical trial involving 124 children demonstrated that *Streptococcus salivarius* BLIS K12 reduced episodes of pharyngitis and other infections over a 3-month period. While the non-randomized design limits the strength of the conclusions, the study suggests a potential role for BLIS K12 in preventing recurrent infections in children.
